FDA Soft Sells GMP Quality Overhaul For Generics; Don’t Be ‘Anxious,’ Woodcock Says
This article was originally published in The Pink Sheet Daily
Executive Summary
‘In some ways our practices have played into the problems we’ve been having,’ CDER director tells GPhA annual meeting as she outlines her plan to ‘radically change’ manufacturing oversight.
You may also be interested in...
PhRMA Awards Celebrate Breakthroughs – And Get Warning On Prices
Merck's Keytruda highlights promise of FDA designation, but Tom Brokaw notes perils of industry's pricing strategy.
Continuous Manufacturing For Generics Is Easy Path To Quality, Woodcock Says
Production flexibility and less regulatory interaction are among advantages, CDER director tells GPhA in effort to woo converts to the technique.
Generic Drug Shortages Threaten Industry’s Reputation, Hamburg Cautions
“We do have to acknowledge some important, though sometimes difficult truths,” the FDA Commissioner tells GPhA annual meeting. While noting that shortages are problems for both brand and generic firms alike, she tells ANDA manufacturers that “perceptions are not always fair, but they still matter.”